PAM50 potentially simplifies underlying breast tumor biology

On September 23, researchers published online in the journal Nature a study of the molecular biology of breast cancer, using the intrinsic subtypes as defined by the PAM50 gene signature as an organizing framework for analyzing genomic and proteomic aberrations. This landmark study both underscores the emergence of the intrinsic subtypes as a powerful taxonomy of breast cancer in research, and PAM50's role as the gold standard for categorizing breast cancer by subtype.    

This study, titled Comprehensive molecular portraits of human breast tumours, represents the most complete description of breast cancer biology to date. The study was an outcome of The Cancer Genome Atlas (TCGA) Initiative, a comprehensive and coordinated effort to accelerate our understanding of the molecular basis of cancer through the application of genome analysis technologies. The study involved the analysis of tissue from 800 breast cancer tumors by a total of six technology platforms, covering genomics, epigenetics, and proteomics.

Intrinsic subtype by PAM50 was used as a primary organizing framework for the analysis and presentation of the data. The research concluded that diverse genetic and epigenetic alterations converge phenotypically into the four main breast cancer subtypes defined by PAM50 - Luminal A, Luminal B, HER2-enriched, and Basal-like.

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, is developing a PAM50-based in vitro diagnostic test for breast cancer. NanoString announced in December 2010 that it had secured an exclusive worldwide license for the PAM50 gene signature from Bioclassifier, LLC to develop in vitro diagnostic and research products for breast cancer on its nCounter® Analysis System.

"This research advances our understanding of the molecular architecture of breast cancer, and reinforces the emergence of intrinsic subtypes by PAM50 as a powerful description of breast cancer biology," said NanoString President & CEO Brad Gray. "We congratulate the authors on this seminal contribution to our understanding of breast cancer, and look forward to the day when analysis of breast cancer tumors by PAM50 will be available to patients worldwide."

The nCounter Analysis System is a fully automated, multi-application digital detection and counting system with a very simple workflow currently intended for research use only. The nCounter system has been employed in basic and translational research since it was first introduced in 2008. NanoString provides assays for gene expression, miRNA analysis and copy number variation.

Source:

NanoString Technologies, Inc.       

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Nanostring. (2019, June 19). PAM50 potentially simplifies underlying breast tumor biology. News-Medical. Retrieved on August 08, 2022 from https://www.news-medical.net/news/20120925/PAM50-potentially-simplifies-underlying-breast-tumor-biology.aspx.

  • MLA

    Nanostring. "PAM50 potentially simplifies underlying breast tumor biology". News-Medical. 08 August 2022. <https://www.news-medical.net/news/20120925/PAM50-potentially-simplifies-underlying-breast-tumor-biology.aspx>.

  • Chicago

    Nanostring. "PAM50 potentially simplifies underlying breast tumor biology". News-Medical. https://www.news-medical.net/news/20120925/PAM50-potentially-simplifies-underlying-breast-tumor-biology.aspx. (accessed August 08, 2022).

  • Harvard

    Nanostring. 2019. PAM50 potentially simplifies underlying breast tumor biology. News-Medical, viewed 08 August 2022, https://www.news-medical.net/news/20120925/PAM50-potentially-simplifies-underlying-breast-tumor-biology.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay